Non Hodgkin Lymphoma Clinical Trial
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.
Primary Objectives: A pilot Study to evaluate the feasibility, safety and tolerability of a two day course per cycle of Bendamustine plus CPI-613 in patients with relapsed and refractory T cell non-hodgkin lymphoma.
Overall response rate (ORR) and disease control rate (DCR) derived from the Lugano classification.
Duration of response (DOR) derived from the Lugano classification.
Progression-Free-Survival (PFS) derived from Lugano classification.
Overall Survival (OS).
Single cell transcriptomics from PMBCs pre- and post-treatment; for correlative analyses of blood PBMC (and possibly excess pre-treatment tumor biopsy) cell population diversity and functional states to reveal potential mechanisms of drug treatment with regard to patient response status.
Patients must meet all of the following inclusion criteria before enrollment:
Histologically or cytologically confirmed PTCL (all subtypes) or CTCL (mycosis fungoides/Sezary syndrome) as defined by 2016 World Health Organization (WHO) classification.
For patients with PTCL:
Patients must have relapsed/refractory disease to one or more systemic therapies.
Patients with CD30-positive lymphoma must have received, be ineligible for, or intolerant to brentuximab vedotin.
Patients with limited prior exposure to Bendamustine (less than 2 full cycles or ≤ 480 mg/m2) may be included, based on PI discretion.
Patients must have measurable disease (e.g., a tumor mass >1 cm or evidence of bone marrow involvement).
For patients with CTCL, Stage IB-IVB mycosis fungoides or Sezary syndrome are eligible
Patients must have relapsed/refractory disease to at least one previous systemic therapy. Psoralen plus ultraviolet light therapy (PUVA) is not considered to be a systemic therapy.
Male and female patients 18 years of age and older
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Expected survival greater than 3 months.
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.
Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.
At least 2 weeks must have elapsed from prior chemotherapy drugs (other than steroids) or radiation
At least 6 weeks must have elapsed from prior autologous stem cell transplant and 12 weeks must have elapsed from prior allogeneic stem cell transplant.
Laboratory values ≤2 weeks must be: Adequate hematological function (absolute neutrophil count [ANC] ≥1,500/mm3, platelets ≥100,000/mm3). In subjects with known bone marrow involvement, ANC must be ≥ 1000/mm3 and platelets ≥75,000/mm3; Adequate hepatic function (aspartate aminotransferase [AST/SGOT] less than or equal to 3x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] less than or equal to 3x UNL (≤5x UNL if liver metastases present), bilirubin less than or equal to 1.5x UNL); Adequate renal function (serum creatinine less than or equal to 1.5 mg/dL or 133 µmol/L).
No evidence of current infection.
Mentally competent, ability to understand and willingness to sign the informed consent form.
Patients with the following characteristics are excluded:
Known cerebral metastases, central nervous system (CNS) or epidural tumor.
History of prior malignancy and considered to be at greater than 30% risk of relapse
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs (steroids are allowed)
Patients with a history of allogeneic transplant must not have ≥ grade 3 graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic immunosuppression.
Serious medical illness that would potentially increase patients' risk for toxicity.
Pregnant women, or women of child-bearing potential not using reliable means of contraception (because the teratogenic potential of CPI-613 is unknown).
Fertile men unwilling to practice contraceptive methods during the study period.
Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
Unwilling or unable to follow protocol requirements.
Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction or symptomatic congestive heart failure.
Evidence of current infection..
Patients with known HIV infection, hepatitis B, or hepatitis C with positive viral load.
Patients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Winston-Salem North Carolina, 27157, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.